Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Single-centre, Randomised, Two-period, Cross-over Study to Assess the Efficacy and Safety of Automated Closed-loop Glucose Control in Adults With Type 1 Diabetes Comparing Ultra-fast Acting Insulin Lispro With Insulin Lispro

Next Previous
Search
Trial Profile

An Open-label, Single-centre, Randomised, Two-period, Cross-over Study to Assess the Efficacy and Safety of Automated Closed-loop Glucose Control in Adults With Type 1 Diabetes Comparing Ultra-fast Acting Insulin Lispro With Insulin Lispro

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin lispro (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms ACOLYTE; ACOLYTE Study

    • Most Recent Events

    • 27 Oct 2023 Status changed from not yet recruiting to recruiting.
    • 04 Aug 2023 Planned initiation date changed from 1 Jul 2023 to 1 Oct 2023.
    • 12 Jun 2023 Planned initiation date changed from 1 May 2023 to 1 Jul 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top